Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial.

JAMA network open·2023
Same author

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.

Lancet (London, England)·2023
Same author

Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0.

Cancers·2023
Same author

Association Between Time-of-Day of Immune Checkpoint Blockade Administration and Outcomes in Metastatic Renal Cell Carcinoma.

Clinical genitourinary cancer·2023
Same author

Unique Spectrum of Activating BRAF Alterations in Prostate Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2023
Same author

Survival outcomes of real world patients with metastatic hormone-sensitive prostate cancer who do not achieve optimal PSA response with intensified androgen deprivation therapy with docetaxel or androgen receptor pathway inhibitors.

Prostate cancer and prostatic diseases·2023

Related Experiment Video

Updated: May 21, 2026

Experimental Metastasis Assay
08:28

Experimental Metastasis Assay

Published on: August 24, 2010

MDM2 binding protein, a novel metastasis suppressor.

Tomoo Iwakuma1, Neeraj Agarwal

  • 1Department of Cancer Biology, University of Kansas Medical Center, 3901 Rainbow blvd., Wahl East, Room 2005, Kansas City, KS 66160, USA. tiwakuma@kumc.edu

Cancer Metastasis Reviews
|June 12, 2012
PubMed
Summary

MDM2 binding protein (MTBP) suppresses tumor metastasis independently of p53. Reduced MTBP expression correlates with poorer survival in head and neck cancers, highlighting its role in cancer progression.

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Related Experiment Videos

Last Updated: May 21, 2026

Experimental Metastasis Assay
08:28

Experimental Metastasis Assay

Published on: August 24, 2010

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • MDM2 binding protein (MTBP) interacts with MDM2, a key inhibitor of tumor suppressor p53.
  • MTBP influences cell proliferation and migration, with implications for tumor progression.
  • Loss of MTBP expression is linked to reduced survival in head and neck squamous cell carcinoma.

Purpose of the Study:

  • To review and summarize the known functions of MTBP in tumor progression.
  • To highlight MTBP's role as a potential metastasis suppressor.
  • To discuss future research directions for MTBP in cancer therapy.

Main Methods:

  • Review of published literature on MTBP function.
  • Analysis of clinical data linking MTBP expression to patient survival.
  • Experimental data on MTBP's effect on cell metastasis and migration in osteosarcoma models.

Main Results:

  • MTBP overexpression inhibits metastasis and cell migration, independent of p53 status.
  • Reduced MTBP expression enhances tumor metastasis and cell migratory potential in mice.
  • MTBP acts as a metastasis suppressor by inhibiting α-actinin-4 function.

Conclusions:

  • MTBP is a significant factor in suppressing tumor metastasis.
  • MTBP's role in cancer progression is independent of the p53 pathway.
  • Further research into MTBP's mechanisms and therapeutic potential is warranted.